View Past PerformanceOncodesign Precision Medicine Société anonyme 대차 대조표 상태재무 상태 기준 확인 0/6주요 정보n/a부채 비율n/a부채이자 보상 비율n/a현금n/a주식n/a총 부채n/a총 자산n/a최근 재무 상태 업데이트업데이트 없음모든 업데이트 표시Recent updatesOncodesign Precision Medicine Reports Final Results of Its Phase 1 Study with Ripk2 Inhibitor Opm-101, with Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1B/2AOct 25Oncodesign Precision Medicine Société anonyme to Report First Half, 2024 Results on Sep 30, 2024Sep 26OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety ProfileJul 17Oncodesign Precision Medicine Société anonyme, Annual General Meeting, Jun 26, 2024Mar 27+ 1 more updateOncodesign Precision Medicine Receives ERDF Fund Totalling €2.1 Million for its Comete ProgramJan 26Oncodesign Precision Medicine Receives ERDF Fund Totalling €2.1 Million for its Comete ProgramJan 25Oncodesign Precision Medicine Société anonyme announced that it has received €22 million in funding from Eurazeo SE and other investorsJan 24+ 1 more updateNew major risk - Shareholder dilution Oct 15Oncodesign Precision Medicine Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy VolunteersOct 05재무 상태 분석부채 대 자본 내역 및 분석대차 대조표건강한 기업 발견하기7D1Y7D1Y7D1YPharmaceuticals-biotech 업계의 건강한 기업.View Dividend
Oncodesign Precision Medicine Reports Final Results of Its Phase 1 Study with Ripk2 Inhibitor Opm-101, with Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1B/2AOct 25
Oncodesign Precision Medicine Société anonyme to Report First Half, 2024 Results on Sep 30, 2024Sep 26
OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety ProfileJul 17
Oncodesign Precision Medicine Société anonyme, Annual General Meeting, Jun 26, 2024Mar 27+ 1 more update
Oncodesign Precision Medicine Société anonyme announced that it has received €22 million in funding from Eurazeo SE and other investorsJan 24+ 1 more update
Oncodesign Precision Medicine Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy VolunteersOct 05